Homemade synthetic drugs surge in US, increasing overdose risks

A 48‑year‑old Army veteran in Columbus, Ohio, is smoking a homemade blend of fentanyl, xylazine and medetomidine, a cocktail that can kill in minutes. He lights a foil packet in a back alley, inhales, and sways as the drug takes hold. The mix costs only a few dollars, yet it is far more dangerous than the heroin that once dominated the scene. Mike, who works at a local pawn shop and gas station, says the drug “will damn near make you do anything.” He is one of many users who rely on these synthetic blends to feed a 20‑year‑old opioid addiction that has become the new norm in many U.S. neighbourhoods.

Synthetic opioids have reshaped the drug crisis. Fentanyl is 50 to 100 times stronger than heroin and is now routinely cut with animal tranquilizers such as xylazine and medetomidine. These substances keep users sedated for longer and, crucially, do not respond to naloxone, the life‑saving nasal spray known as Narcan. In 2022, overdose deaths peaked at 110,000, mostly from opioids, but have fallen to about 70,000 in 2023. The decline masks a shifting landscape: while fatal overdoses are down, the drugs themselves are more lethal and harder to treat. Local residents note that the mix Mike smokes can produce skin ulcers and necrotic wounds that can be fatal. Recovery experts warn that the prevalence of these synthetic blends is pushing the crisis into a new, more deadly phase.

Naloxone remains the frontline response, but its limitations are stark. It can reverse fentanyl but not the added tranquilizers. Emergency crews now carry larger doses of Narcan and are training to recognise signs of xylazine overdose, such as extreme drowsiness and low blood pressure. Law enforcement is tightening controls on precursor chemicals, while researchers are working on new reversal agents. For people like Mike, the risk is high: a single hit can be lethal if the drug is cut with the wrong mix. The government is also expanding public‑health campaigns to raise awareness of these new threats. As the synthetic wave continues, the country faces a new challenge: how to keep up with drugs that are both more potent and harder to counteract.